Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5781)
  3. Review (421)
  4. Editorial (196)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (62)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13278)
  2. Center for Hematologic Malignancies (10612)
  3. GSK Faculty (4482)
  4. Adult Leukemia (3673)
  5. Bone Marrow Transplant (2848)
  6. Lymphoma (2705)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (669)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (340)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3529)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (330)
  5. Haematologica (292)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3806)
  2. Elsevier Inc. (1530)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1009)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13379)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mechanistic insights into immune related toxicities in subjects with relapsed/ refractory follicular lymphoma treated with zandelisib
    Meeting Abstract

    Sasi, B. K.; Martindale, S. P.; Shupe, S. J.; Fernandes, S. M.; Yadav, S.; Machado, J. H.; Phillips, T.; Zelenetz, A. D.; Brown, J. R.
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of single-agent zandelisib administered by intermittent dosing in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Final results of the tidal phase 2 study
    Meeting Abstract

    Zelenetz, A. D.; Jurczak, W.; Ribrag, V.; Linton, K. M.; Collins, G. P.; Bishton, M.; López Jiménez, J.; Dholaria, B.; Mengarelli, A.; Phillips, T. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Population pharmacokinetics and exposure-response analyses from Phase I-III studies support copanlisib dose selection in relapsed indolent non-Hodgkin lymphoma
    Meeting Abstract

    Moss, J.; Garmann, D.; Austin, R.; Hiemeyer, F.; Matasar, M. J.; Zinzani, P. L.; Beckert, V.; Soler, L. M.; Childs, B. H.; Morcos, P. N.
    Blood (2022)

    Fulltext@MSK | Save
  • Updated outcomes from the historical control study SCHOLAR-3 contextualizing ZUMA-3 results of brexucabtagene autoleucel (KTE-X19) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
    Meeting Abstract

    Shah, B. D.; Ghobadi, A.; Oluwole, O. O.; Logan, A. C.; Boissel, N.; Cassaday, R. D.; Leguay, T.; Bishop, M. R.; Topp, M. S.; Tzachanis, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Initial results from SELECT-AML-1, a Phase 2 Study of tamibarotene in combination with venetoclax and azacitidine in RARA-positive newly diagnosed AML patients ineligible for standard induction chemotherapy
    Meeting Abstract

    Kambhampati, S.; McMahon, C. M.; Eghtedar, A.; Pollyea, D. A.; de Botton, S.; Pigneux, A.; Cherry, M.; Ball, B. J.; Borthakur, G.; Cluzeau, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage
    Meeting Abstract

    Vekariya, U. M.; Sullivan-Reed, K.; Toma, M.; Nieborowska-Skorska, M.; Le, B. V.; Caron, M. C.; Kukuyan, A. M.; Podszywalow-Bartnicka, P.; Chitrala, K.; Atkins, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Transient M-proteins: Epidemiology, causes, and the impact of mass spectrometry: The iStopMM study
    Meeting Abstract

    Palmason, R.; Berlanga, O.; Sigurdsson, J. K.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Ekberg, S.; Crowther, M.; Levy, M.; Reed, E. R.; Þórir Oskarsson, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
    Meeting Abstract

    Korde, N.; Diamond, B.; Burge, M.; Hassoun, H.; Landau, H.; Hultcrantz, M.; Mailankody, S.; Maclachlan, K. H.; Shah, U. A.; Derkach, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma: Phase 1b results of SYMPHONY-1
    Meeting Abstract

    Batlevi, C. L.; Salles, G.; Park, S. I.; Phillips, T. J.; Amengual, J. E.; Andorsky, D.; Campbell, P.; McKay, P.; Leonard, J. P.; Sondhi, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from the phase 1/2 BRUIN study
    Meeting Abstract

    Mato, A. R.; Woyach, J. A.; Brown, J. R.; Ghia, P.; Patel, K.; Eyre, T. A.; Munir, T.; Lech-Maranda, E.; Lamanna, N.; Tam, C. S.; more...
    Blood (2022)

    Fulltext@MSK | Save